Endocrinology and Metabolism

Original Article

Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol (SMART-5 Study): Ji Yoon Kim, Nam Hoon Kim, Soo Heon Kwak, Chang Hee Jung, Eun Seok Kang, Jun Sung Moon, Sun Joon Moon, So Yoon Kwon, Jee Hee Yoo, Younghoon Kim, Tae-min Lee, Chung-il Yang, Jae Hyeon Kim, Sang-Man Jin; Received July 26, 2025 Accepted October 13, 2025 Published online December 12, 2025; DOI: https://doi.org/10.3803/EnM.2025.2579 [Epub ahead of print]

2,139 View
68 Download

Abstract PDF PubReader ePub: Background
Stage 2 or 3 connected insulin pens (CIPs) refer to tracking insulin pens that are capable of transmitting insulin dose data via cloud connectivity. Stage 4 CIPs feature a bolus calculator that determines appropriate insulin doses based on real-time continuous glucose monitoring (CGM) data, carbohydrate intake, previous dosing history, and preset parameters. Stage 5 CIPs additionally offer advanced decision-support features, such as education modules and coaching. However, the efficacy and safety of Stage 5 CIPs have not yet been established.
Methods
In this prospective, open-label, parallel-group, multicenter, randomized controlled trial, we will include adults aged ≥19 and <75 years with type 1 or type 2 diabetes receiving multiple daily insulin injections (MDI) and having glycosylated hemoglobin (HbA1c) levels of 7.5% to 12.0%. In total, 152 participants will be randomized in a 1:1 ratio to receive either Stage 5 CIPs with CGM or tracking insulin pens with CGM. Stage 5 CIPs include a Setup Wizard that recommends individualized initial settings and an algorithm that provides advanced insulin dosing guidance based on analyses of each participant’s CGM and insulin injection data. The primary outcome will be the change in HbA1c levels from baseline to week 12 (ClinicalTrials.gov, NCT07004153).
Conclusion
This trial (Stage 5 connected insulin pen for MDI with Advanced decision support in a Randomized Trial [SMART-5 Study]) will determine whether Stage 5 CIPs are superior to tracking insulin pens in improving glycemic control among adults with type 1 or type 2 diabetes treated with MDI. Overall, this study may offer a promising strategy for enhancing the management and outcomes of patients with diabetes.

Review Article

Diabetes, obesity and metabolism
Advances in Continuous Glucose Monitoring: Clinical Applications: So Yoon Kwon, Jun Sung Moon; Endocrinol Metab. 2025;40(2):161-173. Published online April 8, 2025; DOI: https://doi.org/10.3803/EnM.2025.2370

32,218 View
813 Download
18 Web of Science
28 Crossref

Abstract PDF PubReader ePub

Continuous glucose monitoring (CGM) has revolutionized diabetes management, significantly enhancing glycemic control across diverse patient populations. Recent evidence supports its effectiveness in both type 1 and type 2 diabetes management, with benefits extending beyond traditional glucose monitoring approaches. CGM has demonstrated substantial improvements in glycemic control across multiple metrics. Studies report consistent glycosylated hemoglobin reductions of 0.25%–3.0% and notable time in range improvements of 15%–34%. CGM effectively reduces hypoglycemic events, with studies reporting significant reductions in time spent in hypoglycemia. CGM also serves as an educational tool for lifestyle modification, providing real-time feedback that helps patients understand how diet and physical activity affect glucose levels. While skin-related complications remain a concern, technological advancements have addressed many initial concerns. High satisfaction rates and long-term use suggest that device-related issues are manageable with proper education and support. Despite high initial costs, CGM’s prevention of complications and hospitalizations ultimately reduces healthcare expenditures. With appropriate training and support, CGM represents a transformative technology for comprehensive diabetes care.

Citations

Citations to this article as recorded by

Glycemic Control Practices in Intensive Care Units: A National Survey Study
Zeynep Irmak Kaya, Serdar Efe
Cerasus Journal of Medicine.2026; 3(2): 132. CrossRef
Advancements in Continuous Glucose Monitoring: a Revolution in Diabetes Management
Kondreddy Vinod Kumar, Kamal Raj Yerraguntla, Maruthi Prasad Jenne, Abhilash Gadi, Akhila Sepoori, Anusha Gunda, Madhu Sri Gudivada
Biomedical Materials & Devices.2026; 4(3): 3126. CrossRef
Advancements in glucose biosensors: Innovations for wearable and real-time monitoring
Reetu Singh, Priyanshu Nema, Arpana Purohit, Satyamshyam Vishwakarma, Shyamji Tantuway, Pradhumn Namdeo, Ajay Kumar, Vandana Soni, Sushil Kumar Kashaw
Talanta.2026; 299: 129045. CrossRef
Continuous glucose monitoring in high-risk individuals
Zhiyue Chen, Yinbei Zhang, Lin Sun, Weiying Guo
Clinica Chimica Acta.2026; 580: 120733. CrossRef
Scoping review of subcutaneous glucose monitoring techniques
Eva Hrubá, Jan Kubíček, Martin Augustynek
Measurement.2026; 261: 119940. CrossRef
Continuous Glucose Monitoring for Pancreatogenic Diabetes After Total Pancreatectomy
Young Jae Cho, Inhyuck Lee, Yoon Soo Chae, Go‐Won Choi, Younsoo Seo, Youngmin Han, Hye‐sol Jung, Wooil Kwon, Joon Seong Park, Jin‐Young Jang
Journal of Hepato-Biliary-Pancreatic Sciences.2026; 33(3): 208. CrossRef
Use of continuous glucose monitoring in non-intensively managed type 2 diabetes: a Saudi Arabian consensus
Mohammed Almehthel, Abdulghani Al-Saeed, Fahad Al-Sabaan, Faisal Al-Malky, Hawazen Zarif, Lamya Al-Zubaidi, Mohammed E. Al-Sofiani, Omar Abdulaal, Reem Al Argan, Saud Al Sifri, Turki Al-Harbi, Raed Aldahash
Frontiers in Endocrinology.2026;[Epub] CrossRef
Wearable microneedle sensors for continuous interstitial fluid monitoring
Junghyun Cho, Heeju Son, Jayoung Kim, Hyun Seok Song, Wonryung Lee
Biosensors and Bioelectronics.2026; 297: 118385. CrossRef
Efficacy of an AI-Enabled Low Glucose Prediction: A Pooled Performance Analysis With Capillary Blood Glucose as Ground Truth
Timor Glatzer, Ajandek Peak, Eemeli Leppäaho, Patrick Lustenberger, Pau Herrero, Magí Andorrà, Ellen van Maren
Journal of Diabetes Science and Technology.2026;[Epub] CrossRef
Respiratory Signal Processing and Analysis Using Flexible Capacitive Sensor Data
Bernardo A. Vicente, Raquel Sebastião, Alda Marques, Vitor Sencadas
Advanced Materials Technologies.2026;[Epub] CrossRef
Toward continuous and non-invasive monitoring: a scoping review of in vitro blood glucose devices from electrochemistry to optics and micro-system integration
Wanmeng Wang, Chongyu Liu, Peiwen Lin, Suo Li, Yongchao Yao, Zhuqing Wang, Wenchuang (Walter) Hu
Journal of Materials Chemistry B.2026; 14(11): 3383. CrossRef
Biobanking in der Inneren Medizin
Denise Zwanziger
Die Innere Medizin.2026; 67(4): 418. CrossRef
EMERGING DIGITAL TECHNOLOGIES IN MONITORING ENDOCRINE DISORDERS: CONTINUOUS GLUCOSE MONITORING SYSTEMS AND ARTIFICIAL INTELLIGENCE IN THE DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME
Aleksandra Ćwirko-Godycka, Nikola Murawska, Michalina Chodór, Aleksandra Tomaszewska, Kinga Karczewska, Sonia Mojzyk, Maciej Kokoszka, Aleksandra Mierniczek, Natalia Dymel, Ryszard Feret
International Journal of Innovative Technologies in Social Science.2026;[Epub] CrossRef
Changes in Continuous Glucose Monitoring Metrics During the Initial Phase of a Korean Medicine–Based Weight Reduction Program: A Retrospective Observational Study
Minwoo Bang, Suyong Shin, Jungsang Kim, Minwhee Kang, Donghun Lee, Junho Kim, Chunghee Kim, Jiyoung Son, Seonghyeon Jeon, Byungsoo Kang
Journal of Korean Medicine.2026; 47(1): 87. CrossRef
Long-term impact of continuous glucose monitoring on glycemic and metabolic control in type 1 diabetes: A three-year real-world evaluation
Ayman Al Hayek, Wael M. Al Zahrani, Haifa F. AlOtaibi, Jehad Y. Saleh, Mohammed A. Al Dawish
Primary Care Diabetes.2026; 20(3): 326. CrossRef
Non-enzymatic sweat sensors for pediatric continuous glucose monitoring: a systematic review of engineering readiness and the cost-accuracy trade-off
Oluwanifemi Temiloluwa Bolaji, Emmanuel Dominic Ephraim, Olumhense Benedict Adoghe, Deborah Daramola, Emmanuel Francis Kibuebu
BMC Biomedical Engineering.2026;[Epub] CrossRef
Identifying Actionable Glucose Patterns in Type 1 and Type 2 Diabetes Using Continuous Glucose Monitoring and Algorithmic Pattern Recognition
Timor Glatzer, Ajandek Peak, Eemeli Leppäaho, Patrick Lustenberger, Pau Herrero, Magí Andorrà, Ellen van Maren
Journal of Diabetes Science and Technology.2026;[Epub] CrossRef
The Current Landscape of Remote Patient Monitoring Regarding Diabetes Mellitus and Hypoglycemia: Protocol for a Scoping Review
Mathew J Stephen, Baylor Akhavan, Melinda B Chu, Kavita Batra, Roberto Sagaribay
JMIR Research Protocols.2026; 15: e88197. CrossRef
Prehospital identification of hypoglycemia-induced seizure using a smartphone-linked continuous glucose monitoring application
Kenji Harada, Yuji Okazaki, Toshihisa Ichiba
The American Journal of Emergency Medicine.2026; 107: 13. CrossRef
Advanced Drug Delivery Approaches for Antidiabetic Agents: Strategies to Enhance Bioavailability, Efficacy, and Patient Compliance
H G Srusti, K Darshini , K V Poorvika , Bramhotri Rout
Journal of Drug Delivery and Therapeutics.2026; 16(5): 182. CrossRef
Use of technology and AI tools in type 2 diabetes
Jothydev Kesavadev, Mohamed Abdul Khader M, Anjana Basanth
Best Practice & Research Clinical Endocrinology & Metabolism.2026; : 102130. CrossRef
Adjunctive Treatment with GLP-1 and Dual GLP-1/GIP Receptor Agonists for People with Type 1 Diabetes: Consensus Report and Practical Guidelines for Safe Use
Satish K. Garg, Halis K. Akturk, Samita Garg, Roy W. Beck, Natalie J. Bellini, Petter Bjornstad, Anders L. Carlson, Jim Carroll, Kelly Close, Christophe De Block, Klemen Dovc, Gregory P. Forlenza, Francesco Giorgino, Julie Heverly, Irl B. Hirsch, Mareda L
Diabetes Technology & Therapeutics.2026;[Epub] CrossRef
Associations of time in tight range, time in range, and glycated hemoglobin with albuminuria in type 1 diabetes: A cross-sectional study
Ji Yoon Kim, Seohyun Kim, Sang Ho Park, Jin A Lee, So Hyun Cho, Rosa Oh, Myunghwa Jang, You-Bin Lee, Gyuri Kim, Kyu Yeon Hur, Jae Hyeon Kim, Sang-Man Jin
Diabetes Research and Clinical Practice.2025; 226: 112325. CrossRef
SMART CARE FOR DIABETES: INTEGRATING TECHNOLOGY AND LIFESTYLE FOR BETTER OUTCOMES
Aleksandra Maciejczyk, Katarzyna Krupa, Weronika Głowacz, Janusz Świeczkowski-Feiz
International Journal of Innovative Technologies in Social Science.2025;[Epub] CrossRef
Identification of clinically meaningful automatically detected postprandial glucose excursions in individuals with type 1 diabetes using personal continuous glucose monitoring
Sang Ho Park, Rosa Oh, Seohyun Kim, Seung Hee Yang, Hanna Lee, Ji Yoon Kim, So Hyun Cho, Soojin Park, Gyuri Kim, Jae Hyeon Kim, Sang–Man Jin
Diabetes Research and Clinical Practice.2025; 229: 112951. CrossRef
Bridging the digital divide: student-led literacy initiatives in diabetes management
Pedro Almeida Moyano, Mohammed Raddaoui, Andrea de Barros Coscelli Ferraz, Gustavo José Martiniano Porfírio, Luciana Aparecida Campos, Ovidiu Constantin Baltatu
Frontiers in Clinical Diabetes and Healthcare.2025;[Epub] CrossRef
Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol
Ji Yoon Kim, Nam Hoon Kim, Soo Heon Kwak, Chang Hee Jung, Eun Seok Kang, Jun Sung Moon, Sun Joon Moon, So Yoon Kwon, Jee Hee Yoo, Younghoon Kim, Tae-min Lee, Chung-il Yang, Jae Hyeon Kim, Sang-Man Jin
Endocrinology and Metabolism.2025;[Epub] CrossRef
Evolution and Future of Glucose Monitoring: From Blood Glucose Meters to Continuous Systems and Their Projected Impact in the Middle East and North Africa (MENA) Region
Omar Darkhabani, Abdalla Ahmed
Cureus.2025;[Epub] CrossRef

Original Article

Diabetes, obesity and metabolism
Plasma C-Peptide Levels and the Continuous Glucose Monitoring-Defined Coefficient of Variation in Risk Prediction for Hypoglycemia in Korean People with Diabetes Having Normal and Impaired Kidney Function: So Yoon Kwon, Jiyun Park, So Hee Park, You-Bin Lee, Gyuri Kim, Kyu Yeon Hur, Jae Hyeon Kim, Sang-Man Jin; Endocrinol Metab. 2025;40(2):268-277. Published online February 27, 2025; DOI: https://doi.org/10.3803/EnM.2024.2083

5,347 View
107 Download
5 Web of Science
6 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We aimed to investigate the predictive values of plasma C-peptide levels and the continuous glucose monitoring (CGM)-defined coefficient of variation (CV) in risk prediction for hypoglycemia in Korean people with diabetes with normal and impaired kidney function.
Methods
We analyzed data from 1,185 participants diagnosed with type 1 and type 2 diabetes who underwent blinded professional CGM between January 2009 and May 2021 at outpatient clinics. We explored correlations among CGM-defined CV, plasma C-peptide levels, and time below range at <70 and 54 mg/dL across different kidney function categories.
Results
In patients with chronic kidney disease (CKD) stages 1–2 (n=934), 89.3% who had a random plasma C-peptide level higher than 600 pmol/L exhibited a CV of ≤36%. Among those in CKD stage 3 (n=161) with a random plasma C-peptide level exceeding 600 pmol/L, 66.7% showed a CV of ≤36%. In stages 4–5 of CKD (n=90), the correlation between random C-peptide levels and CV was not significant (r=–0.05, P=0.640), including cases with a CV greater than 36% despite very high random plasma C-peptide levels. Random plasma C-peptide levels and CGM-assessed CV significantly predicted hypoglycemia in CKD stages 1–2 and 1–5, respectively.
Conclusion
The established C-peptide criteria in Western populations are applicable to Korean people with diabetes for hypoglycemic risk prediction, unless kidney function is impaired equivalent to CKD stage 3–5. The CGM-defined CV is informative for hypoglycemic risk prediction regardless of kidney function.

Citations

Citations to this article as recorded by

Continuous glucose monitoring in high-risk individuals
Zhiyue Chen, Yinbei Zhang, Lin Sun, Weiying Guo
Clinica Chimica Acta.2026; 580: 120733. CrossRef
The evolution of C-peptide's role in diabetes care
Laura Briggs, Alexander Read, Sarah Darch, Emma L. Williams, Wann Jia Loh, Julia S. Kenkre
Current Opinion in Endocrinology, Diabetes & Obesity.2026; 33(1): 16. CrossRef
Antidiabetic Potential of Brewed Arabica Coffee: Modulation of GLUT4, Insulin, and Glucagon in STZ‐Induced Rats
Yusni Yusni, Hanifah Yusuf, Said Usman, Iflan Nauval, Hasanuddin Hasanuddin, Fahmi Ichwansyah, Nurul Mahmudati, Eric Gumpricht
Journal of Nutrition and Metabolism.2026;[Epub] CrossRef
Recent Advances in the Application of C-Peptide in Type 2 Diabetes Management: From Biomarker to Clinical Decision Tool
茜许
Advances in Clinical Medicine.2026; 16(04): 3314. CrossRef
Plasma C-Peptide Level and Continuous Glucose Monitoring-Derived Coefficient of Variation as a Predictable Risk Factor for Hypoglycemia in Koreans with Diabetes
Seung-Hyun Ko
Endocrinology and Metabolism.2025; 40(2): 198. CrossRef
Beneficial Role of Increased Glucose Infusion in Decompensated Type 2 Diabetes Patient
Marie Ticha, Ondrej Sobotka, Pavel Skorepa, Lubos Sobotka
Diabetology.2025; 6(6): 47. CrossRef

Brief Reports

Adrenal gland
Comparative Analysis of Liquid Chromatography-Tandem Mass Spectrometry and Radioimmunoassay in Determining Plasma Aldosterone Concentration and Plasma Renin Activity for Primary Aldosteronism Screening: So Yoon Kwon, Kyeong-Jin Kim, Soo-Youn Lee, Jae Hyeon Kim; Endocrinol Metab. 2024;39(6):965-969. Published online November 15, 2024; DOI: https://doi.org/10.3803/EnM.2024.1985

3,855 View
80 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) accurately measures plasma aldosterone concentration (PAC), but its correlation with radioimmunoassay (RIA), equivalent RIA levels, and optimal cutoff for PAC and aldosterone-to-renin ratio (ARR) in primary aldosteronism (PA) screening have not been determined in a Korean population. Our study of 127 patients who underwent diagnostic testing for PA showed that the LC-MS/MS and RIA methods have good correlation, with a mean bias of 29.3% for PAC. An LC-MS/MS PAC level of 11.7 ng/dL was equivalent to an RIA PAC level of 15 ng/dL. Receiver operating characteristic curve analysis showed that an LC-MS/MS PAC level of 10.3 ng/dL and LC-MS/MS ARR level of 20.0 provided sensitivity of 73.1% with a specificity of 57.3% and sensitivity of 92.3% with a specificity of 14.7%, respectively. When the LC-MS/MS method is used for PA screening, an adjustment of cutoff values is necessary.

Citations

Citations to this article as recorded by

Magnetic bead-assisted extraction combined with LC–MS/MS for simultaneous quantification of aldosterone and related steroids in human plasma
Yudong Chu, Qin Su, Ziyuan Huang, Chenyi Yuan, Shazhou Ye, Xueyan Bian
Analytical and Bioanalytical Chemistry.2026; 418(1): 343. CrossRef

Adrenal Gland
Aldosterone Immunoassay-Specific Cutoff Value for Seated Saline Suppression Test for Diagnosing Primary Aldosteronism: So Yoon Kwon, Jiyun Park, So Hee Park, So Hyun Cho, You-Bin Lee, Soo-Youn Lee, Jae Hyeon Kim; Endocrinol Metab. 2022;37(6):938-942. Published online December 6, 2022; DOI: https://doi.org/10.3803/EnM.2022.1535

10,999 View
228 Download
4 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

A seated saline loading test (SLT) using liquid chromatography-tandem mass spectrometry (LC-MS/MS) is one of the most accepted confirmatory tests of primary aldosteronism. However, LC-MS/MS is time-consuming and is not widely available in diagnostic laboratories compared to immunoassay. With immunoassay, it is unknown whether SLT in the seated position is more accurate than that of the supine position, and a cutoff value of post-seated SLT plasma aldosterone concentration (PAC) must be established in the Korean population. Ninety-eight patients underwent SLT in both positions, and post-SLT PAC was measured by LC-MS/MS and radioimmunoassay. We confirmed primary aldosteronism if post-seated SLT PAC by LC-MS/MS exceeded 5.8 ng/dL. The area under the receiver operating characteristic curve was greater for seated than supine SLT (0.928 vs. 0.834, P=0.003). The optimal cutoff value of post-seated SLT by radioimmunoassay was 6.6 ng/dL (sensitivity 83.3%, specificity 92.2%).

Citations

Citations to this article as recorded by

Investigating the cut-off values of captopril challenge test for primary aldosteronism using the novel chemiluminescent enzyme immunoassay method: a retrospective cohort study
Yuta Tezuka, Kei Omata, Yoshikiyo Ono, Kengo Kambara, Hiroki Kamada, Sota Oguro, Yuto Yamazaki, Celso E. Gomez-Sanchez, Akihiro Ito, Hironobu Sasano, Kei Takase, Tetsuhiro Tanaka, Hideki Katagiri, Fumitoshi Satoh
Hypertension Research.2024; 47(5): 1362. CrossRef
Usefulness of the Upright Posture Test in the Diagnosis of Primary Aldosteronism
Nada Younes, Matthieu St-Jean, Marie-Josée Desrochers, Eric Therasse, Mathieu Latour, Isabelle Bourdeau, André Lacroix
Journal of the Endocrine Society.2024;[Epub] CrossRef
Screening and treatment of endocrine hypertension focusing on adrenal gland disorders: a narrative review
Seung Min Chung
Journal of Yeungnam Medical Science.2024; 41(4): 269. CrossRef
Comparative Analysis of Liquid Chromatography-Tandem Mass Spectrometry and Radioimmunoassay in Determining Plasma Aldosterone Concentration and Plasma Renin Activity for Primary Aldosteronism Screening
So Yoon Kwon, Kyeong-Jin Kim, Soo-Youn Lee, Jae Hyeon Kim
Endocrinology and Metabolism.2024; 39(6): 965. CrossRef

First
Prev
Page of 1
Next
Last

Search